公开(公告)号：US20050059143A1

公开(公告)日：2005-03-17

申请号：US10661329

申请日：2003-09-12

申请人： Allan Louderback

发明人： Allan Louderback

IPC分类号： A61K39/395 ,  C07K16/34 ,  C12N15/00 ,  C11D17/00

CPC分类号： C07K16/34 ,  A61K39/39591

摘要： A process for making Solvent Detergent (SD) treatment effective against non-enveloped viruses. The process stipulates using prequalified concentrations of formaldehyde and phenol with SD treatments. In particular, serial or combined use of 100 to 10,000 parts per million of formaldehyde and/or 100 to 10,000 parts per million of phenol with an associated SD treatment process are disclosed.

摘要翻译： 制备溶剂洗涤剂（SD）治疗对非包膜病毒有效的方法。 该方法规定使用甲醛和苯酚的预标准浓度进行SD处理。 特别地，公开了连续或组合使用100至10,000份/百万份甲醛和/或100至10,000份/百万份苯酚和相关的SD处理方法。

公开(公告)号：US20040157215A1

公开(公告)日：2004-08-12

申请号：US10803653

申请日：2004-03-18

申请人： Cambridge Antibody Technology Limited ,  Medical Research Council

发明人： John McCafferty ,  Anthony Richard Pope ,  Kevin Stuart Johnson ,  Henricus Renerus Jacobus Mattheus Hoogenboom ,  Andrew David Griffiths ,  Ronald Henry Jackson ,  Kaspar Philipp Holliger ,  James David Marks ,  Timothy Piers Clackson ,  David John Chiswell ,  Gregory Paul Winter ,  Timothy Peter Bonnert

IPC分类号： C12Q001/70 ,  C12Q001/68

CPC分类号： C40B40/02 ,  B01J2219/00718 ,  C07K16/00 ,  C07K16/18 ,  C07K16/34 ,  C07K16/40 ,  C07K16/44 ,  C07K16/462 ,  C07K16/468 ,  C07K19/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/41 ,  C07K2319/735 ,  C12N15/1037 ,  C12N15/62 ,  C12N15/73 ,  G01N33/53 ,  G01N33/6857

摘要： A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA. Using this method libraries of DNA encoding respective chains of such multimeric sbp members may be combined, thereby obtaining a much greater genetic diversity in the sbp members than could easily be obtained by conventional methods.

公开(公告)号：US20030215454A1

公开(公告)日：2003-11-20

申请号：US10376518

申请日：2003-03-01

发明人： A. Mark Colb ,  Herman K. Gold

IPC分类号： A61K039/395

CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/34 ,  C07K2317/31

摘要： Binding of red blood cells (RBCs) to exposed subendothelial surfaces. According to one aspect of the invention, RBCs bind to a subendothelial surface that has been exposed by angioplasty so as to block the deposition of platelets onto the exposed surface, thereby impeding thrombosis and the triggering of restenosis by deposited platelets. A bispecific antibody is used to mediate the binding of RBCs to the exposed subendothelial surface, the bispecific antibody having a first antigen binding site directed against an RBC surface marker and a second antigen binding site directed against a subendothelial epitope. The bispecific antibody is preferably introduced into the bloodstream just prior to the performance of the angioplasty and is introduced in a quantity sufficient to bind a high percentage of RBCs. According to another aspect of the invention, RBCs are drawn from a patient, treated and then administered back to the patient for targeted drug delivery. The RBC treatment comprises coating the RBCs with two types of bispecific antibodies, the first type being adapted to bind the RBCs to an exposed subendothelial surface, the second type being adapted to removably bind the RBCs to a drug. The drug is then loaded onto the second type of bispecific antibody.

摘要翻译： 将红细胞（RBC）与暴露的内皮下表面结合。 根据本发明的一个方面，RBC结合已经通过血管成形术暴露的内皮下表面，以阻止血小板沉积在暴露的表面上，从而阻止血栓形成并引起沉积的血小板的再狭窄。 双特异性抗体用于介导RBC与暴露的内皮下表面的结合，双特异性抗体具有针对RBC表面标志物的第一抗原结合位点和针对内皮下表位的第二抗原结合位点。 优选在执行血管成形术之前将双特异性抗体引入血流中，并以足以结合高百分比的RBCs的量引入双特异性抗体。 根据本发明的另一方面，从患者抽取RBC，将其治疗并随后给予患者用于靶向药物递送。 RBC治疗包括用两种类型的双特异性抗体包被RBC，第一类型适于将RBC结合到暴露的内皮内表面，第二类型适于将RBC可移除地结合至药物。 然后将药物加载到第二种类型的双特异性抗体上。

公开(公告)号：US06551830B2

公开(公告)日：2003-04-22

申请号：US09789378

申请日：2001-02-20

申请人： L. Scott Rodkey ,  Marwan A. Yared ,  Kenneth J. Moise, Jr.

发明人： L. Scott Rodkey ,  Marwan A. Yared ,  Kenneth J. Moise, Jr.

IPC分类号： G01V3100

CPC分类号： G01N33/80 ,  A61K38/00 ,  C07K14/705 ,  C07K16/34 ,  Y10S435/975 ,  Y10S436/824 ,  Y10T436/10

摘要： Disclosed are novel protein and peptide compositions comprising soluble and bound forms of immunologically-active blood group antigens including mammalian Rh antigens. In preferred embodiments methods for the isolation and purification of serologically-active human Rh antigens such as D, c, C, E, and e are disclosed. Also disclosed are methods for the adsorption of immunologically-active Rh antigens to solid supports. Diagnostic kits, methods, and devices for the detection of Rh antibodies in clinical and non-clinical samples are also disclosed. Devices, compositions and methods for the isolation, purification and quantitation of anti-Rh antibodies from solution are also provided.

公开(公告)号：US20020090370A1

公开(公告)日：2002-07-11

申请号：US09753007

申请日：2001-01-02

发明人： Alex Zhu

IPC分类号： A61K039/395 ,  C07H021/04 ,  C08B037/00 ,  C07K007/06

CPC分类号： C07K16/18 ,  A61K39/001 ,  A61K2035/122 ,  C07K14/705 ,  C07K16/065 ,  C07K16/34

摘要： The present invention provides a porcine antigen that binds to human xenoreactive antibodies. The porcine antigen differs from the known porcine xenoantigens in that the antigen does not include an nullGal epitope. The present invention also provides methods to purify the porcine antigen of the invention, as well as agents that bind to the antigen. The antigen may be used to generate antibodies against the antigen. The antigen is useful for detecting the presence of human xenoreactive antibodies against the antigen in blood and blood compositions, and antibodies against the antigen may be used to detect the presence of the antigen in samples. The invention also provides methods and pharmaceutical compositions for reducing a host rejection response to a porcine xenograft. Finally, a method to treat human blood or blood-derived compositions to reduce the level of human xenoantibodies is disclosed.

摘要翻译： 本发明提供了结合人类异反应性抗体的猪抗原。 猪抗原与已知的猪异种抗原不同，因为抗原不包括αGal表位。 本发明还提供了纯化本发明猪抗原的方法以及与抗原结合的试剂。 抗原可用于产生针对抗原的抗体。 该抗原可用于检测血液和血液组合物中针对抗原的人异种活性抗体的存在，并且可以使用针对抗原的抗体来检测样品中抗原的存在。 本发明还提供用于降低对猪异种移植物的宿主排斥反应的方法和药物组合物。 最后，公开了一种治疗人血液或血液衍生组合物以降低人类异种抗体水平的方法。

公开(公告)号：US20020018751A1

公开(公告)日：2002-02-14

申请号：US09327764

申请日：1999-06-07

发明人： DOMINIQUE P. BRIDON ,  DOMINIQUE BLANCHARD ,  ALAN M. EZRIN ,  PHILLIPE POULETTY

IPC分类号： A61K049/00

CPC分类号： B82Y5/00 ,  A61K38/00 ,  A61K39/385 ,  A61K47/6839 ,  A61K47/6849 ,  A61K47/6898 ,  A61K47/6901 ,  A61K51/0406 ,  A61K2039/505 ,  A61K2039/6056 ,  A61K2039/625 ,  A61K2123/00 ,  C07K14/005 ,  C07K14/70514 ,  C07K16/08 ,  C07K16/16 ,  C07K16/34 ,  C07K16/44 ,  C12N2740/16122

摘要： Compositions and methods of non-invasive diagnosis are provided. The imaging agents include a linking groups and a reactive entity capable of reaction with a reactive functionality to form a covalent bond therewith. The imaging agents may be in the form of a bifunctional anchor molecule. The bifunctional anchor molecules have a functional group capable of activation which, when activated, may form a covalent bond with a reactive functionality on a target protein present in the mammalian vascular system, thereby nullanchoringnull the molecule to that target protein. The bifunctional anchors are also conjugated, either directly or indirectly, to a diagnostic agent of interest which provides the ability to diagnostically and non-invasively image the mammalian vascular space. Vascular targets include both cellular- and noncellular-associated proteins present in the mammalian vascular system. The methods find use for numerous applications arising from the ability to diagnostically image the mammalian vascular space over an extended period of time or to preferentially diagnostically image only a specific cell type or compartment of the mammalian vascular space.

摘要翻译： 提供非侵入性诊断的组成和方法。 成像剂包括能够与反应性官能团反应以形成与其共价键的连接基团和反应性实体。 成像剂可以是双功能锚定分子的形式。 双功能锚定分子具有能够活化的官能团，当被激活时，其可以与存在于哺乳动物血管系统中的靶蛋白上的反应性官能团形成共价键，从而将分子“锚定”到该靶蛋白。 双功能锚定体也直接或间接地缀合到感兴趣的诊断剂，其提供诊断和非侵入性成像哺乳动物血管空间的能力。 血管靶标包括存在于哺乳动物血管系统中的细胞和非细胞相关蛋白。 该方法可用于许多应用，这是由于能够在延长的时间段内对哺乳动物血管空间进行诊断图像的能力，或优先诊断性地仅对哺乳动物血管空间的特定细胞类型或隔室进行成像。

公开(公告)号：US20010018419A1

公开(公告)日：2001-08-30

申请号：US09789378

申请日：2001-02-20

申请人： Board of Regents

发明人： L. Scott Rodkey ,  Marwan A. Yared ,  Kenneth J. Moise JR.

IPC分类号： G01N033/554 ,  A61K038/17

CPC分类号： G01N33/80 ,  A61K38/00 ,  C07K14/705 ,  C07K16/34 ,  Y10S435/975 ,  Y10S436/824 ,  Y10T436/10

摘要： Disclosed are novel protein and peptide compositions comprising soluble and bound forms of immunologically-active blood group antigens including mammalian Rh antigens. In preferred embodiments methods for the isolation and purification of serologically-active human Rh antigens such as D, c, C, E, and e are disclosed. Also disclosed are methods for the adsorption of immunologically-active Rh antigens to solid supports. Diagnostic kits, methods, and devices for the detection of Rh antibodies in clinical and non-clinical samples are also disclosed. Devices, compositions and methods for the isolation, purification and quantitation of anti-Rh antibodies from solution are also provided.

公开(公告)号：US06280958B1

公开(公告)日：2001-08-28

申请号：US09488157

申请日：2000-01-20

申请人： L. Scott Rodkey ,  Marwan A. Yared ,  Kenneth J. Moise, Jr.

发明人： L. Scott Rodkey ,  Marwan A. Yared ,  Kenneth J. Moise, Jr.

IPC分类号： G01N3353

CPC分类号： G01N33/80 ,  A61K38/00 ,  C07K14/705 ,  C07K16/34 ,  Y10S435/975 ,  Y10S436/824 ,  Y10T436/10

摘要： Disclosed are novel protein and peptide compositions comprising soluble and bound forms of immunologically-active blood group antigens including mammalian Rh antigens. In preferred embodiments methods for the isolation and purification of serologically-active human Rh antigens such as D, c, C, E, and e are disclosed. Also disclosed are methods for the adsorption of immunologically-active Rh antigens to solid supports. Diagnostic kits, methods, and devices for the detection of Rh antibodies in clinical and non-clinical samples are also disclosed. Devices, compositions and methods for the isolation, purification and quantitation of anti-Rh antibodies from solution are also provided.

摘要翻译： 公开了包含可溶性和结合形式的免疫活性血型抗原（包括哺乳动物Rh抗原）的新型蛋白质和肽组合物。 在优选实施方案中，公开了用于分离和纯化血清学活性的人Rh抗原如D，c，C，E和e的方法。 还公开了用于将免疫活性Rh抗原吸附到固体支持物上的方法。 还公开了用于在临床和非临床样品中检测Rh抗体的诊断试剂盒，方法和装置。 还提供了用于从溶液中分离，纯化和定量抗Rh抗体的装置，组合物和方法。

公开(公告)号：US06228618B1

公开(公告)日：2001-05-08

申请号：US08955526

申请日：1997-10-22

申请人： Raymond Paul Field

发明人： Raymond Paul Field

IPC分类号： C12N1509

CPC分类号： C12N9/6459 ,  C07K14/52 ,  C07K14/61 ,  C07K16/00 ,  C07K16/065 ,  C07K16/34 ,  C12N1/38 ,  C12N5/163 ,  C12N2500/36 ,  C12Y304/21069

摘要： Methods for enhancing the production of tissue plasminogen activator (tPA) in cell culture are disclosed. The methods involve culturing tPA-producing cells in growth media supplemented with an alkanoic acid or salt thereof at a concentration which enhances tPA production. The most preferred methods utilize butyric acid or sodium butyrate at a concentration of between 0.5 mM and 2.5 mM.

摘要翻译： 公开了增强细胞培养物中组织纤溶酶原激活物（tPA）生产的方法。 所述方法包括以增强tPA产生的浓度培养补充有链烷酸或其盐的生长培养基中的tPA产生细胞。 最优选的方法是使用浓度为0.5mM和2.5mM之间的丁酸或丁酸钠。

公开(公告)号：US6103233A

公开(公告)日：2000-08-15

申请号：US477900

申请日：1995-06-07

申请人： Philippe Pouletty ,  Christine Pouletty

发明人： Philippe Pouletty ,  Christine Pouletty

IPC分类号： A61K38/00 ,  A61K38/16 ,  A61K39/385 ,  A61K39/395 ,  A61K47/48 ,  C07K14/16 ,  C07K14/73 ,  C07K16/08 ,  C07K16/16 ,  C07K16/28 ,  C07K16/34 ,  C07K16/44 ,  C07K16/46 ,  C07K16/18

CPC分类号： B82Y5/00 ,  A61K39/385 ,  A61K47/48523 ,  A61K47/48561 ,  A61K47/48753 ,  A61K47/48776 ,  C07K14/005 ,  C07K14/70514 ,  C07K16/08 ,  C07K16/16 ,  C07K16/34 ,  C07K16/44 ,  A61K2039/505 ,  A61K2039/6056 ,  A61K2039/625 ,  A61K38/00 ,  C12N2740/16122

摘要： First and second compounds are provided, where the first compound is administered to a mammalian host into blood for covalent bonding to blood components, where the components have an extended lifetime in the blood stream. The first compound comprises an active functionality and an agent of interest or a first binding entity. A second compound may be subsequently administered to the patient, which comprises a second binding entity, complementary to the first binding entity and an agent of interest. By virtue of binding to long-lived blood components, the half-life of the agent of interest is greatly extended in vivo.

摘要翻译： 提供了第一和第二化合物，其中第一化合物被施用于哺乳动物宿主进入血液以与血液成分共价结合，其中组分在血流中具有延长的使用寿命。 第一化合物包含活性官能团和感兴趣的试剂或第一结合实体。 随后可将第二化合物施用于患者，其包含与第一结合实体和感兴趣的药剂互补的第二结合实体。 由于结合长寿命的血液成分，感兴趣的药剂的半衰期在体内大大延长。